A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.


Updates from The Motley Fool

Latest updates on Seattle Genetics from Fool.com.


Stock Performance

SGEN vs. S&P 500 | 2 Year Performance
View Interactive SGEN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Seattle Genetics.
Current Price: $47.37
Prev Close: $47.98
Open: $47.52
Bid: $41.10
Ask: $49.00
Day's Range: $46.75 - $47.94
52wk Range: $26.02 - $49.66
Volume: 529,626
Avg Vol 775,473
Market Cap: $6.61B
P/E (ttm): -63.13
EPS (ttm): -$0.76
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Seattle Genetics.
CAPS Rating 4 out of 5
 
467 Outperform
33 Underperform
CAPS All Stars
 
84 Outperform
10 Underperform

How do you think Seattle Genetics will perform against the market?



You pick for Seattle Genetics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Clay B. Siegall, CEO

86% Approve

Based on 20 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Seattle Genetics.

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers